ENTITY

Diurnal Limited (DNL LN)

7
Analysis
Health CareUnited Kingdom
Diurnal Limited engages in the research and development of products to deliver therapeutics to humans in the United Kingdom. The company targets patient needs in chronic endocrine (hormonal) diseases. Its product pipeline includes Infacort that is in Phase III clinical trial for use in the control of Adrenal Insufficiency in neonates, infants, small children, pre-pubescent children; and Chronocort, a cortisol replacement product, which is in Phase III clinical trial for the life-long treatment of congenital adrenal insufficiency and adrenal insufficiency. The company also develops native testosterone formulation for hypogonadism; and TRI4COMBI for hypothyroidism. Diurnal Limited was incorporated in 2015 and is based in Cardiff, the United Kingdom.
more
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
x